Zenas BioPharma (ZBIO) FCF Margin (2024 - 2025)
Zenas BioPharma (ZBIO) recorded quarterly FCF Margin of 370.69% in Q1 2025, up 52.02% quarter-over-quarter from 772.56% in Q4 2024.
Zenas BioPharma (ZBIO) FCF Margin (2024 - 2025) Analysis & Trends
Zenas BioPharma's FCF Margin history runs 2 years deep, the most recent figure standing at 370.69% for Q1 2025.
- In Q1 2025, FCF Margin changed N/A year-over-year to 370.69%; the TTM figure through Dec 2025 stood at 1723.51% (up 67259.0% YoY), while the FY2025 annual figure was 1723.51%, up 67259.0% from the prior year.
- FCF Margin was 370.69% for Q1 2025 at Zenas BioPharma, up from 772.56% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 370.69% in Q1 2025 to a low of 772.56% in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -3.98% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 43.35% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Zenas BioPharma | 1.10 Bn | 379.43 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | -370.69% |
| Dec 31, 2024 | -772.56% |